IGF1R and non-small cell lung carcinoma: Although a multicenter phase III trial was discontinued because of the increased risk for severe toxicities of IGF1R antibody [35], phase II trials suggested that high free serum IGF1 levels are correlated with better prognosis in NSCLC patients undergoing combined therapy with erlotinib and IGF1R inhibitor [36].